Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650505 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 233
- Enrollment target
NCT02650505 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 233 participants.
The verdict
NCT02650505, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 233 participants
- Enrollment target
Study Summary
This is a randomized, single-center, controlled, within-subject comparison study assessing the sensitization potential of the investigational product, LEO 43204 gel under open conditions in healthy volunteers. LEO 43204 Gel and Vehicle Gel will be applied to adjacent sites on the infrascapular area of the back. Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema and other signs of cutaneous irritation. Following induction, subjects will have a 10 to 14-day Rest Phase, after which they will enter the Challenge Phase, which consists of one 48-hour application to a naive site on the opposite side of the back. Observations at the naive site during Challenge and the patterns of reactivity during the Induction Phase will provide a basis for an interpretation of contact sensitization. A total of 10 applications will be made over a period of approximately 6-8 weeks.
Interventions
- DRUG LEO 43204
- DRUG LEO 43204 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02650505
The ClinicalTrials.gov registry entry for NCT02650505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LEO 43204 is the first listed.
NCT02650505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02650505 about?
NCT02650505 is a clinical study titled "A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel". This is a randomized, single-center, controlled, within-subject comparison study assessing the sensitization potential of the investigational product, LEO 43204 gel under open conditions in healthy volunteers. LEO 43204 Gel and Vehicle Gel will be applied to adjacent sites on the infrascapular area...
What is the current status of trial NCT02650505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 233 participants. The study started on 2016-02. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02650505?
The interventions under investigation include: LEO 43204 (DRUG), LEO 43204 Vehicle (DRUG).
Who is sponsoring clinical trial NCT02650505?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.